Race Oncology Ltd (RAC) - Total Liabilities
Based on the latest financial reports, Race Oncology Ltd (RAC) has total liabilities worth AU$1.20 Million AUD (≈ $847.04K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Race Oncology Ltd generate cash to assess how effectively this company generates cash.
Race Oncology Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Race Oncology Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Race Oncology Ltd's assets to evaluate the company's liquid asset resilience ratio.
Race Oncology Ltd Competitors by Total Liabilities
The table below lists competitors of Race Oncology Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
M3-Brigade Acquisition V Corp. Class A Ordinary shares
NASDAQ:MBAV
|
USA | $19.58 Million |
|
Hansae Co
KO:105630
|
Korea | ₩825.57 Billion |
|
Steelcast Limited
NSE:STEELCAS
|
India | Rs508.80 Million |
|
Taiwan Optical Platform Co Ltd
TW:6464
|
Taiwan | NT$9.55 Billion |
|
Greenpanel Industries Limited
NSE:GREENPANEL
|
India | Rs7.57 Billion |
|
Transcontinental Realty Investors
NYSE:TCI
|
USA | $276.69 Million |
|
Kizilbuk Gayrimenkul Yatirim Ortakligi AS
IS:KZBGY
|
Turkey | TL10.62 Billion |
|
Strattec Security Corporation
NASDAQ:STRT
|
USA | $129.23 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Race Oncology Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RAC market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Race Oncology Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Race Oncology Ltd (2011–2025)
The table below shows the annual total liabilities of Race Oncology Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.48 Million ≈ $1.05 Million |
-22.85% |
| 2024-06-30 | AU$1.92 Million ≈ $1.36 Million |
+66.39% |
| 2023-06-30 | AU$1.15 Million ≈ $814.97K |
-18.74% |
| 2022-06-30 | AU$1.42 Million ≈ $1.00 Million |
+170.95% |
| 2021-06-30 | AU$523.11K ≈ $370.13K |
+114.70% |
| 2020-06-30 | AU$243.65K ≈ $172.40K |
+26.82% |
| 2019-06-30 | AU$192.12K ≈ $135.94K |
-37.97% |
| 2018-06-30 | AU$309.71K ≈ $219.14K |
-14.82% |
| 2017-06-30 | AU$363.57K ≈ $257.25K |
-7.16% |
| 2016-06-30 | AU$391.62K ≈ $277.10K |
+229.70% |
| 2015-06-30 | AU$118.78K ≈ $84.04K |
-10.05% |
| 2014-06-30 | AU$132.05K ≈ $93.43K |
-99.93% |
| 2013-12-31 | AU$191.01 Million ≈ $135.15 Million |
+1611781.86% |
| 2013-06-30 | AU$11.85K ≈ $8.38K |
-100.00% |
| 2012-12-31 | AU$264.98 Million ≈ $187.49 Million |
-20.07% |
| 2012-06-30 | AU$331.51 Million ≈ $234.56 Million |
+21.34% |
| 2011-06-30 | AU$273.20 Million ≈ $193.31 Million |
-- |
About Race Oncology Ltd
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across vari… Read more